BMY
ACCE-researchedOverview
ACCE thesis
Bristol-Myers Squibb manufactures and markets prescription pharmaceuticals across oncology, immunology, and cardiovascular disease, with blockbuster drugs including Revlimid, Opdivo, and Eliquis generating over $30 billion in combined annual revenue. The company's deep immunology franchise, anchored by CAR-T therapies and checkpoint inhibitors, creates sustainable competitive moats in high-barrier therapeutic areas where switching costs are prohibitive. BMY's $74 billion Celgene acquisition in 2019 is finally paying dividends as the integration completes and cost synergies flow through to margins. Trading at 9.2x forward earnings despite 38.7% ROE signals the market hasn't recognized the earnings power emerging from this restructured portfolio. The Revlimid patent cliff that spooked investors is largely behind us, with new drug launches and pipeline assets like deucravacitinib positioning BMY for accelerating growth through 2025.
- highElevated leverage ratioDebt/Equity of 2.44 signals heavy debt load, likely from acquisitions, constraining financial flexibility and amplifying downside risk.
- highSharp QoQ revenue declineQuarter-over-quarter revenue fell 8.1%, suggesting near-term demand weakness or product cycle headwinds despite modest YoY growth of 2.6%.
- moderateInsider selling, no buyingLast 10 disclosed transactions show $3.70M in sales and zero buys, indicating insiders are not adding exposure at current prices.
- moderateLarge forward P/E discountForward P/E of 9.1 vs trailing 16.6 implies consensus expects significant earnings decline ahead, not just multiple compression.
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
Price
Valuation
INVESTORSix independent models converge on one confidence-weighted fair value, with full methodology and editable assumptions.
- +All six models: DCF, P/E and EV/EBITDA comps, Graham, dividend discount, residual income
- +Scenario bands, sensitivity tornado, and the 5-year historical valuation range
- +Editable DCF workbench with saved scenarios
Quality
INVESTORThe full quality picture: conviction breakdown, earnings quality, score history, and backtested returns.
- +Conviction score breakdown and earnings-quality grade
- +Growth / value / quality / momentum component scores
- +90-day score history and score-threshold backtests
Analysts
Wall Street consensus
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
- +Price-target low / average / high vs the current price, with implied upside
- +Forward revenue and EPS consensus by fiscal year
- +ACCE fair-value models lined up against the Street
Smart Money
PROFollow the institutions: 13F position changes, insider trades, and active 13D activist filings.
- +Quarter-over-quarter institutional position changes
- +Recent open-market insider transactions
- +Active 13D activist filings and top holders
Compare
Where it sits vs peers
Algorithmic peers (6)
| Ticker | Company | Mcap | P/E | ROE | D/E | Yield | Quality | |
|---|---|---|---|---|---|---|---|---|
| PFE | Pfizer Inc. Common Stock | $158.1B | 36.5 | 5.0% | 0.74 | 6.2% | - | Compare |
| GSK | GSK plc American Depositary Shares (Each representing two Ordinary Shares) | $102.3B | 16.2 | 33.4% | 1.03 | 3.6% | - | Compare |
| SNY | Sanofi ADS | $101.8B | 23.0 | 5.7% | 0.26 | 5.7% | - | Compare |
| SAN.PA | Sanofi | $101.7B | 22.9 | 5.7% | 0.26 | 5.5% | - | Compare |
| GSK.L | GSK | $100.4B | 15.9 | 33.4% | 1.03 | 3.6% | - | Compare |
| NVO | Novo Nordisk A/S Common Stock | $175.8B | 9.9 | 59.8% | 0.67 | 4.2% | - | Compare |
Sector report card
Where BMY ranks against its sector peers on each metric.
News and Record
Press releases mentioning this company
- Business Wire•Sep 18, 2026Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026
- Business Wire•Sep 17, 2026Bristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years
- Business Wire•Sep 16, 2026Bristol Myers Squibb Announces Dividend
Ask anything, Pro feature
Ask questions about this stock in plain language. Answered from company fundamentals + recent valuations.